Drugs / Chimeric dengue serotype (1, 2, 3, 4)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00730288 | Aug 2006 → Aug 2007 | Dengue hemorrhagic fever | Sanofi | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Chimeric dengue serotype (1, 2, 3, 4) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00730288 ↗ |
| Known as | TDV | “All participants received one subcutaneous injection of tetravalent dengue vaccine (TDV) and were followed for 180 days.” PMID 21976579 ↗ Oct 2011 |
| Modality | Vaccine | “A dengue vaccine effective against all four serotypes is urgently needed.” PMID 21976579 ↗ Oct 2011 |
| Route | Subcutaneous | “All participants received one subcutaneous injection of tetravalent dengue vaccine (TDV)” PMID 21976579 ↗ Oct 2011 |